| Small molecule inhibitors targeting activator protein 1 (AP-1) miniperspective N Ye, Y Ding, C Wild, Q Shen, J Zhou Journal of medicinal chemistry 57 (16), 6930-6948, 2014 | 235 | 2014 |
| Direct activation of Bax protein for cancer therapy Z Liu, Y Ding, N Ye, C Wild, H Chen, J Zhou Medicinal research reviews 36 (2), 313-341, 2016 | 222 | 2016 |
| Discovery and development of natural product oridonin-inspired anticancer agents Y Ding, C Ding, N Ye, Z Liu, EA Wold, H Chen, C Wild, Q Shen, J Zhou European journal of medicinal chemistry 122, 102-117, 2016 | 159 | 2016 |
| Synthesis, self-assembly, and characterization of PEG-coated iron oxide nanoparticles as potential MRI contrast agent C Yue-Jian, T Juan, X Fei, Z Jia-Bi, G Ning, Z Yi-Hua, D Ye, G Liang Drug development and industrial pharmacy 36 (10), 1235-1244, 2010 | 126 | 2010 |
| Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection J Xu, EA Wold, Y Ding, Q Shen, J Zhou Molecules 23 (2), 474, 2018 | 105 | 2018 |
| Targeting Kruppel-like factor 5 (KLF5) for cancer therapy Y Gao, Y Ding, H Chen, H Chen, J Zhou Current topics in medicinal chemistry 15 (8), 699-713, 2015 | 81 | 2015 |
| Cystathionine-β-synthase inhibition for colon cancer: enhancement of the efficacy of aminooxyacetic acid via the prodrug approach C Chao, JR Zatarain, Y Ding, C Coletta, AA Mrazek, N Druzhyna, ... Molecular Medicine 22, 361-379, 2016 | 73 | 2016 |
| Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis FJ Bohanon, X Wang, C Ding, Y Ding, GL Radhakrishnan, C Rastellini, ... Journal of Surgical Research 190 (1), 55-63, 2014 | 66 | 2014 |
| BH4 domain of Bcl-2 as a novel target for cancer therapy Z Liu, C Wild, Y Ding, N Ye, H Chen, EA Wold, J Zhou Drug discovery today 21 (6), 989-996, 2016 | 64 | 2016 |
| Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines JS Rudra, Y Ding, H Neelakantan, C Ding, R Appavu, S Stutz, JD Snook, ... ACS chemical neuroscience 7 (5), 546-552, 2016 | 62 | 2016 |
| A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5 J Wu, Y Ding, CH Chen, Z Zhou, C Ding, H Chen, J Zhou, C Chen Cancer letters 380 (2), 393-402, 2016 | 57 | 2016 |
| Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3) H Chen, Z Yang, C Ding, A Xiong, C Wild, L Wang, N Ye, G Cai, ... European journal of medicinal chemistry 82, 195-203, 2014 | 57 | 2014 |
| ent-Kaurane-based regio-and stereoselective inverse electron demand hetero-Diels–Alder reactions: synthesis of dihydropyran-fused diterpenoids C Ding, L Wang, H Chen, C Wild, N Ye, Y Ding, T Wang, MA White, ... Organic & biomolecular chemistry 12 (42), 8442-8452, 2014 | 49 | 2014 |
| The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells Z Zhang, C Zhang, Y Ding, Q Zhao, L Yang, J Ling, L Liu, H Ji, Y Zhang Food and chemical toxicology 63, 38-47, 2014 | 40 | 2014 |
| Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fibrosis in vivo H Chen, AA Mrazek, X Wang, C Ding, Y Ding, LJ Porro, H Liu, C Chao, ... Bioorganic & medicinal chemistry 22 (13), 3393-3404, 2014 | 39 | 2014 |
| Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis D Li, H Wang, Y Ding, Z Zhang, Z Zheng, J Dong, H Kim, X Meng, Q Zhou, ... Cancer letters 424, 97-108, 2018 | 36 | 2018 |
| Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis FJ Bohanon, X Wang, BM Graham, C Ding, Y Ding, GL Radhakrishnan, ... journal of surgical research 199 (2), 441-449, 2015 | 33 | 2015 |
| Regio-and stereospecific synthesis of oridonin D-ring aziridinated analogues for the treatment of triple-negative breast cancer via mediated irreversible covalent warheads Y Ding, D Li, C Ding, P Wang, Z Liu, EA Wold, N Ye, H Chen, MA White, ... Journal of medicinal chemistry 61 (7), 2737-2752, 2018 | 32 | 2018 |
| Modulation of Bax and mTOR for cancer therapeutics R Li, C Ding, J Zhang, M Xie, D Park, Y Ding, G Chen, G Zhang, ... Cancer research 77 (11), 3001-3012, 2017 | 30 | 2017 |
| DDQ-promoted dehydrogenation from natural rigid polycyclic acids or flexible alkyl acids to generate lactones by a radical ion mechanism Y Ding, Z Huang, J Yin, Y Lai, S Zhang, Z Zhang, L Fang, S Peng, ... Chemical communications 47 (33), 9495-9497, 2011 | 30 | 2011 |
